It has been two years since we’ve
had a post devoted to fluorine NMR. Though I don't share Teddy’s “fetish” for 19F-based
screening, I do think the technique can be quite powerful, as demonstrated in a
recent J. Med. Chem. paper by Jo
Alen, Markus Schade, and their colleagues at Grünenthal GmbH.
The researchers were interested
in sepiapterin reductase, which is abbreviated as SPR but which I’ll spell out
to avoid confusion with surface plasmon resonance. This enzyme performs the
last step in the production of tetrahydrobiopterin, an essential cofactor for multiple
enzymes, including some that synthesize neurotransmitters and produce nitric
oxide. Sepiapterin reductase has been proposed as a target for non-opioid-based
pain medications.
The primary assay involved
displacement of a fluorine-containing inhibitor that binds in the substrate
site of the enzyme; thus, the researchers could use 19F NMR without
requiring fluorinated fragments. A total of 4750 fragments were screened at 250
µM, initially in pools of 12. The 26 hits were then tested in an enzymatic
assay, and 21 showed activity better than 75 µM. The best, compound 3, was
sub-micromolar.

This is a nice story that
illustrates a not-infrequent frustration: after identifying the initial
nanomolar hit from a small library, the researchers likely thought improving
potency still further would be easy. Instead, it took more than 60 analogs just
to gain another order of magnitude. That said, 57 nM is nothing to sneeze at. And
this situation is certainly preferable to the more common alternative of
starting with a weak fragment that remains weak no matter what you do to it!
No comments:
Post a Comment